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ABSTRACT
MGMT (O6-Methylguanine-DNA Methyltransferase) suppresses tumor development by removing alkyl adduct, while 
SPOCK2 (SPARC/Osteonectin CWCV and Kazal-like domains proteoglycan) abolishes the inhibition of membrane-type 
matrix metalloproteinases (MT-MMP) which leads to angiogenesis. Hence, MGMT methylation may initiate malignant cells 
transformation. In contrast, SPOCK2 methylation is hypothesized not to be a common event in diffuse large B-cell lymphoma 
(DLBCL). In this study, we examined the methylation status of MGMT and SPOCK2 in DLBCL as in Malaysia the information 
is extremely lacking. A total of 88 formalin-fixed paraffin-embedded tissue of patients diagnosed with DLBCL from the 
year 2006 to 2013 were retrieved from Hospital Universiti Sains Malaysia, Kelantan and Hospital Tengku Ampuan Afzan, 
Pahang. Methylation-specific polymerase chain reaction (MSP) was used to examine the methylation status of both genes. 
Interestingly, methylation of MGMT was detected in all the 88 DLBCL samples, whereas SPOCK2 was found to be methylated 
in 83 of 88 (94.3%) DLBCL cases. Our study showed a remarkably high percentage of promoter methylation of both 
MGMT and SPOCK2 genes. Our finding also negates initial expectation that SPOCK2 methylation would be an uncommon 
event in the majority of DLBCL cases. This study has shown a very high percentage of promoter methylation of MGMT and 
SPOCK2 in the DLBCL cases studied by MSP, using archival lymphoma tissues. Nonetheless, additional research is needed 
to quantitatively evaluate MGMT and SPOCK2 methylation, and to analyse gene expression and/or protein expression in 
order to further understand the role of MGMT and SPOCK2 methylation in the pathogenesis of DLBCL.
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ABSTRAK
MGMT (O6-Methylguanine-DNA Methyltransferase) merencat perkembangan tumor dengan menyingkirkan alkyl adduct, 
manakala SPOCK2 (SPARC/Osteonectin CWCV and Kazal-like domains proteoglycan) menghalang perencatan matriks 
metaloproteinase jenis membran (MT-MMP) yang menyebabkan angiogenesis. Oleh itu, metilasi MGMT mampu menyebabkan 
inisiasi transformasi sel malignan. Sebaliknya, secara hipotesis, metilasi SPOCK2 bukanlah penyumbang yang lazim 
dalam pembentukan diffuse large B-cell lymphoma (DLBCL). Dalam kajian ini, status metilasi MGMT dan SPOCK2 pada 
DLBCL telah ditentukan memandangkan kurangnya kajian tentang ini di Malaysia. Sebanyak 88 tisu parafin pesakit yang 
didiagnosis dengan DLBCL dari tahun 2006 hingga 2013 telah dikumpulkan daripada Hospital Universiti Sains Malaysia, 
Kelantan dan Hospital Tengku Ampuan Afzan, Pahang. Reaksi rantaian polimerase yang spesifik-metilasi (MSP) telah 
diaplikasikan bagi memeriksa status metilasi kedua-dua gen. Menariknya, metilasi MGMT dikesan dalam kesemua 88 
sampel DLBCL, manakala metilasi SPOCK2 dikesan dalam 83 daripada 88 (94.3%) kes DLBCL. Kajian ini menunjukkan 
peratusan metilasi promoter gen MGMT dan SPOCK2 yang amat tinggi. Penemuan ini juga menafikan jangkaan awal yang 
metilasi SPOCK2 adalah jarang berlaku dalam kebanyakan kes DLBCL. Kajian ini telah menunjukkan peratusan metilasi 
promoter MGMT dan SPOCK2 yang sangat tinggi dalam kes DLBCL yang dikaji melalui kaedah MSP menggunakan arkib 
tisu limfoma. Walau bagaimanapun, penyelidikan lanjut diperlukan untuk menilai metilasi MGMT dan SPOCK2 secara 
kuantitatif, dan untuk menganalisa ekspresi gen dan/atau ekspresi protein untuk lebih memahami peranan metilasi MGMT 
dan SPOCK2 dalam patogenesis DLBCL.
Kata kunci: MGMT; SPOCK2; MSP; DLBCL; metilasi
INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is an aggressive 
non Hodgkin lymphoma accounting for 30% of lymphoid 
cancers, with median age of 70 years (Hunt & Reichard 
2008). Overall, in Malaysia, lymphoma is ranked the 
sixth most common cancer among males and eighth in 
females (National Cancer Registry Report 2007). DLBCL is 
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heterogeneous in morphologic features, immunophenotypes, 
genetic changes and clinical behaviour (Scott et al. 2014; 
Wang et al. 2010). Research in recent years has provided 
valuable insight into the molecular mechanisms involved 
in the pathogenesis of DLBCL. Amongst the findings include 
pathways leading to immune escape, genetic lesions 
leading to constitutive NF-κB activity and chronic active 
BCR signaling, deregulation of BCL6 activity, disruption 
of the terminal differentiation pathway and epigenetic 
modification (Pasqualucci 2013).
Epigenetic modification in particular DNA methylation 
has been intensively studied and is implicated in 
lymphomagenesis. DNA methylation is a covalent 
addition of a methyl group (CH3) to the 5’ carbon position 
of cytosine by DNA methyltransferases (DNMTs), thus 
triggering histone deacetylases (HDACs) to deacetylate 
and literally change the chromatin structure (Baylin 2005). 
Hence, the genes would not be in a readable state and 
would fail to be transcribed by transcriptional factors. In 
cells of the normal state, during tissue differentiation and 
development, transcription-relevant control regions in the 
genome become selectively de-or upmethyl ated to allow 
for transcription of a restricted set of genes within a given 
tissue (Li et al. 2013). In the pathogenesis of DLBCL, DNA 
methylation has been shown to be disrupted. The aberrant 
methylation involving hypermethylation of gene regulatory 
regions can lead to transcriptional silencing and hence 
resulting in poor expression of tumour suppressor gene 
and certain growth-regulatory proteins. Recent studies 
have further suggested that regulation of gene expression 
by DNA methylation patterning is complex and it is not a 
simple “on” or “off” switch for gene expression (Jiang et 
al. 2013).
The MGMT (O6-Methylguanine-DNA Methyltransferase) 
is a DNA repair gene located on chromosome 10q26. It 
encodes DNA repair protein that removes alkyl groups 
from the O6 positions of guanine an important site for 
DNA alkylation to the active cysteine site within its own 
sequence thereby preventing the formation of lethal cross-
links and other mutagenic effects (Esteller et al. 1999, 
Mehrzad et al. 2014; Smith-Sørensen et al. 2002). This 
single-enzymatic pathway is termed as suicidal reaction 
as for each lesion repaired, one MGMT molecule would be 
inactivated (Esteller et al. 1999). When MGMT expression 
is repressed in cancers, this is often due to methylation of 
its promoter region (Hegi et al. 2005). The presence of 
MGMT methylation was reported in many types of human 
malignancies such as gliomas, colorectal carcinoma, 
non-small cell lung carcinoma and lymphoma (Mulero-
navarro & Esteller 2008). A methylation profile study 
conducted by Yoon et al. demonstrated that epigenetic 
inactivation of MGMT ranging from 12.5% to 37.5% 
among the different types of non-Hodgkin lymphoma 
(Yoon et al. 2008). Specifically, they found MGMT gene 
to be methylated in 30.4% of DLBCL cases. Additionally, 
the immunohistochemistry (IHC) detection of MGMT gene 
hypermethylation in DLBCL was validated by Ucella et 
al. (2009) using the quantitative real-time methylation-
specific PCR assay. 27% of the DLBCL cases in their study 
were MGMT-negative at IHC; however, there was a good 
correlation between the presence of MGMT expression and 
the unmethylated status of the DLBCL cases.
SPOCK2 (SPARC/Osteonectin CWCV and Kazal-like 
domains proteoglycan) gene located on chromosome 10q22 
encodes a protein testican 2, a member of the testican 
group of extracellular chondroitin and heparin sulfate 
proteoglycans. Testicans are involved in the regulation 
of extracellular protease cascade (Chung et al. 2008; 
Hartmann et al. 2012). Testican 2 may contribute to ECM 
remodeling by regulating function(s) of other testican 
family members and the role has mainly been explored in 
the central nervous system. Nakada et al. (2003) found that 
testican 2 uniquely abrogates the inhibition of membrane-
type matrix metalloproteinases (MT-MMP) enzyme by other 
testican proteins and for that, testican 2 was suggested 
to be associated with malignant behaviour of astrocytic 
tumours. Matrix metalloproteinases (MMPs) are a family 
of ECM degrading enzymes, which play important role in 
the angiogenesis related to tumour cells growth (Sounni 
et al. 2011).
In this study we examined the methylation status of the 
2 genes, MGMT (O6-Methylguanine-DNA Methyltransferase) 
and SPOCK2 (SPARC/Osteonectin CWCV and Kazal-
like domains proteoglycan) in DLBCL as in Malaysia 
information is still lacking. In fact, published studies related 
to SPOCK2 and lymphoma is scarce. We hypothesise that 
promoter methylation of SPOCK2 would not be a common 
event in DLBCL.
MATERIALS AND METHODS
This study was approved by the Research Ethics Committee 
of International Islamic University Malaysia (IREC) and 
Universiti Sains Malaysia (JEPeM). In all, 25 and 63 
formalin fixed paraffin embedded (FFPE) DLBCL tissue 
blocks were retrieved from the Department of Pathology of 
Hospital Tengku Ampuan Afzan (HTAA) Kuantan, Pahang 
and Hospital Universiti Sains Malaysia (HUSM) Kubang 
Kerian, Kelantan, respectively. The inclusion criteria are 
cases which have been diagnosed as DLBCL according to 
WHO classification 2008. The exclusion criteria are cases 
of DLBCL with inadequate tissue samples, external referral 
cases and/or incomplete demographic data. The samples 
included consisting of more than 70% tumour cells which 
were collected from year 2006 to 2013. However, due to 
incomplete data on stages and grades, as well as cancer 
progression, we were not able to classify all cases according 
to the aforementioned criteria. Overall, the samples were 
from 35 males and 53 females with a median age of 55 
years old (range, 1-84 years). Five reactive lymph node 
tissues were obtained from HTAA.
Genomic DNA was extracted using the E.Z.N.A® 
FFPE DNA kit (Omega Biotek, US) following protocol 
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specifications by the manufacturer. Extracted DNA 
was subjected to bisulfite treatment using the EZ DNA 
Methylation-Lightning™ kit (Zymo Research, Orange, 
CA). For each of the samples, 200-500 ng DNA was 
incubated with Lightning Conversion reagent at 98°C for 
8 minutes and 54°C for 60 minutes. In a Zymo-Spin™ IC 
Column, the solution was reincubated at room temperature 
for 20 minutes after the addition of L-Desulphonation 
Buffer. Finally, the bisulfite-treated DNA was eluted in a 
total volume of 20 µL in Elution Buffer. Sodium bisulfite 
converts all unmethylated cytosines to uracil leaving the 
methylated cytosines intact.
The MGMT and SPOCK2 fragments were amplified 
using the methylation specific primers as shown in Table 
1. In this study, we designed the primers for SPOCK2 by 
using MethPrimer, a software that is available online 
(Li & Dahiya 2002). The PCR mixture contained 10 ng 
of bisulfite-treated DNA, ZymoTaqTM PreMix (1X), and 
0.4 µM (MGMT) or 0.2 µM (SPOCK2) of each primer in a 
final volume of 20 µL. The PCR cycling conditions were 
as follows: 95°C for 10 minutes; then 40 cycles of 95°C 
for 30 seconds, 40 seconds at 60°C (MGMT unmethylated), 
40 seconds at 59°C (MGMT methylated) and 40 seconds at 
55°C (SPOCK2 unmethylated and methylated), and 72°C 
for 40 seconds; and a final extension of 7 minutes at 
72°C. A mixture of 5 µL of each PCR product and 2 µl of 
DNA loading dye was electrophoresed on a 2% ethidium-
bromide stained agarose gel, and visualised under UV 
illumination.
Pearson’s Chi-square test of SPSS version 12.0 was 
used to identify the association between MGMT and SPOCK2 
methylation status with the demographic parameters 
of the patients. p < 0.05 was considered to indicate a 
statistically significant difference with 95% confidence 
intervals in order to determine the effect of each variable 
on outcome. 
TABLE 1. Primer Sequences
  Gene   Primer sequences in 5’-3’ orientation Product sizes (bp)
 MGMT M F TTTCGACGTTCGTAGGTTTTCGC 81
   R GCACTCTTCCGAAAACGAAACG
  U F TTTGTGTTTTGATGTTTGTAGGTTTTTGT 93
   R AACTCCACACTCTTCCAAAAACAAAACA
      (Yoon et al. 2008)
 SPOCK2 M F GATTTTCGGTAATTTTATGGAGGAC 113
   R CTTAACAACCCTACGAACTCACGT
  
  U F TTTTTGGTAATTTTATGGAGGATGA 111
   R CTTAACAACCCTACAAACTCACATC
      (Li & Dahiya 2002)
 Abbreviations: M = methylated; U = unmethylated; F = forward; R = reverse; bp = basepair.
RESULTS AND DISCUSSION
In all, a total of 88 FFPE tissue blocks of patients diagnosed 
with DLBCL were examined for MGMT and SPOCK2 
methylation status. Methylation of MGMT was detected in 
all the 83 cases including the five reactive lymph nodes 
tissues analysed. SPOCK2 was found to be methylated 
in 83 of the 88 (94.3%) DLBCL cases. We also detected 
SPOCK2 methylation in three of the five reactive lymph 
nodes. Representative results of PCR products for MGMT 
and SPOCK2 genes are as illustrated in Figure 1 and 2, 
respectively. No association between gene methylation 
status with age and gender of patients were seen.
This study reports promoter methylation of MGMT in 
all the DLBCL cases studied and the result is considered 
remarkably high. As no similar studies have been conducted 
in Malaysia or even in the South East Asia region, we are 
not able to compare our results regionally. However, a study 
from the Middle East revealed a high percentage of MGMT 
methylation (71%; 71 of 100 cases studied) in DLBCL (Al-
Kuraya et al. 2005). Studies from Korea and Japan reported 
a much lower percentage, 30.4% and 38.8% respectively 
(Hiraga et al. 2006; Yoon et al. 2008). An Italian series also 
reported a lower percentage of MGMT methylation (36%, 
30/84 cases) (Esteller et al. 2002). Recently, Kristensen et 
al. (2013) examined MGMT methylation in DLBCL using MSP 
and allelic MSP-pyrosequencing analyses and revealed that 
by the respective methods, 22% and 19% of 148 DLBCL 
cases exhibited MGMT methylation.
Inactivation of MGMT may initiate carcinogenesis as 
it codes for a protein that removes alkyl adducts from 
the O6 position of guanine. Alkylated guanine is likely to 
mispair with thymine during DNA replication (Candiloro 
& Dobrovic 2009). Alkylation damage from a variety of 
environmental sources (such as alkylating environmental 
pollutants and tobacco-specific carcinogens) is a common 
occurrence and thus loss of MGMT function may give rise 
to a mutator phenotype (Candiloro & Dobrovic 2009). 
Although promoter methylation of MGMT has been shown 
in various studies to be a useful marker for predicting 
increased overall survival in patients with DLBCL and a 
predictive marker related to respond to chemotherapy with 
alkylating agents, for most cancers, studies that relate MGMT 
activity to therapeutic outcome following O6-alkylating 
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drugs are still lacking (Candiloro & Dobrovic 2009; 
Christmann et al. 2011; Hiraga et al. 2006; Lee et al. 2009;). 
We however did not determine the prognostic significance 
of this methylation status in our patients.
Interestingly, we found the five reactive lymph nodes 
analysed also exhibited MGMT methylation. Sidhu and 
colleagues reported that the frequency of epigenetic MGMT 
inactivation was significantly higher among smokers, 
alcohol drinkers and meat eaters as compared to non-
smokers, non-alcoholic drinkers and vegetarians (Sidhu 
et al. 2010). Unhealthy social habits appear to harm the 
normal regulation of epigenetic homeostasis. We are not 
able to verify these factors in our cases as this study was 
on archival tissues, nevertheless the findings by Sidhu et 
al. (2010) may partially explain the methylation observed 
in the reactive lymph nodes (Sidhu et al. 2010). Also thus 
far available data shows that the expression of MGMT 
varies greatly in normal tissues and in some cases this 
has been related to cancer predisposition (Christmann 
et al. 2011). Quantitative methylation studies such as by 
pyrosequencing would be beneficial as it could determine 
the threshold that discriminate DNA methylation in normal 
versus tumour tissues.
FIGURE 1. Representative MSP results for MGMT. (a) Sample 7, 8, 9, 10, 11 and 12 = methylated (b) Sample 13, 14, 15, 18, 19 and 20 
= methylated (c) Reactive lymph nodes, N1, N2, N3, N4 and N5 = methylated. Abbreviations: M = marker; m = methylated,  
u = unmethylated; N = reactive lymph nodes
FIGURE 2. Representative MSP results for SPOCK2. (a) Sample 1 = unmethylated, sample 3 and 4 = methylated (b) Sample 17 = 
methylated (c) Sample 21 and 6 = unmethylated (d) Sample 2 and 5 = methylated (e) Reactive lymph nodes, N1, N3 and N5 = 
methylated, N2 and N5 = unmethylated Abbreviations: M = marker; m = methylated, u = unmethylated; N = reactive lymph nodes
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This study also identifies promoter methylation 
of SPOCK2 in 94.3% of DLBCL cases. Three of the five 
reactive lymph nodes analysed also exhibited methylation 
of SPOCK2. This finding negates our initial expectation 
that SPOCK2 methylation would be an uncommon event 
in the majority of DLBCL cases. In fact only 5 cases (6%) 
studied were negative for the methylation. Initially we had 
postulated that promoter methylation of SPOCK2 would 
not be a common event in DLBCL since this gene codes 
for testican 2 that functions to abolish the inhibition of 
membrane-type matrix metalloproteinases (MT-MMP) 
enzyme by other testican proteins. MMPs are a family of 
ECM degrading enzymes thereby may play crucial role in 
promoting angiogenesis related to tumour cells growth 
and metastasis (Georges et al. 2012; Nakada et al. 2003; 
Sounni et al. 2011). Aggressive tumour cells that express 
MT-MMP have been shown to proliferate rapidly due to high 
development rate of vascularisation within accumulated 
tumour cells (Seiki & Yana 2003). High expression of 
testican 2 was formerly reported in malignant astrocytic 
tissues (Nakada et al. 2003). Chung et al. (2008) reported 
that SPOCK2 was found to be epigenetically silenced in the 
large proportion of prostate and colon cancers but did not 
discuss the possible contributions of methylated SPOCK2 
in the pathogenesis of those cancers. Thus, our finding 
of a very high percentage of SPOCK2 need to be further 
explored.
CONCLUSION
This study has shown very high percentage of promoter 
methylation of MGMT and SPOCK2 genes in the DLBCL 
cases studied by MSP, using archival lymphoma tissues. 
Nonetheless, more research is needed to quantitatively 
evaluate MGMT and SPOCK2 methylation, and to analyse 
gene expression and/or protein expression in order to further 
understand the role of MGMT and SPOCK2 methylation in the 
pathogenesis of DLBCL and to correlate the findings with 
the clinicopathological parameters.
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